Minerva Neurosciences shares crushed under depression flop, development halted

head and brain
Central nervous system disorders remain tough to crack for all biopharmas. (American Heart Association)

First, Sage Therapeutics was hit this month with a big failure in depression. Now, Minerva Neurosciences (the namesake, incidentally, of the Roman goddess Minerva) is following suit.

The biotech, shares of which were off around 30% in premarket trading Thursday morning, posted dismal data out of its phase 2b trial test of MIN-117 in patients with moderate to severe major depressive disorder (MDD) with anxiety.

It failed to beat placebo in its primary endpoints and missed its key secondaries, echoing a recent failure by rival central nervous system (CNS) biotech Sage and its key phase 3 trial in MDD, which also missed its primary endpoint by failing to beat out placebo.

Featured Webinar

From Concept to Market: Overcoming the Challenges of Manufacturing and Clinical Trials

In this webinar we will reveal the inner workings of the manufacturing and pharmacy department of a CRO/CDMO, so you understand the different regulatory and operational considerations faced by a clinical research pharmacy.

Learn how CRO/CDMOs successfully address operational and regulatory challenges for pharmaceutical and biotechnology clients; and how this can make the difference between study success or failure.

MIN-117 is related to serotonin and dopamine, two neurotransmitters in the brain. MIN-117 is meant to block a specific subtype of serotonin receptor called 5-HT1A. When 5-HT1A is blocked, anxiety and mood can be regulated.

The drug is also meant to prevent the reuptake of serotonin and dopamine, which increases the amount of serotonin and dopamine in the brain and is tied to an improvement in mood in individuals suffering from MDD, as well as modulate the levels of Alpha-1a and 1b, which further modulates serotonin and dopamine.

But this has simply failed to outdo a sham treatment. This also looks like the end of the line for the drug—in MDD, at least. CNS remains a tough nut to crack for all biopharmas, and the failures come in a year when Big Pharma has been actively divesting and spinning out CNS assets amid a miserable success rate.

RELATED: Minerva's sleep drug bests Ambien, placebo in dose-finding study

“We are obviously disappointed with the results despite the trial having been very well executed,” said Remy Luthringer, Ph.D., executive chairman and CEO of Minerva. “We express our sincere appreciation to all of the patients, the investigators and their staff who participated in this trial. At present, we have no plans for further clinical development of the molecule in MDD.”

Suggested Articles

With the closure of its sixth venture capital round, the Swiss health data firm Sophia Genetics has added another $110 million to its coffers.

French biotech Genfit is on its way out of fatty liver R&D after a phase 3 flop, but compatriot Poxel is on its way up with a phase 2 win.

Genentech committed $200 million in upfront and near-term payments, plus up to $515 million in more distant milestones, for the exclusive rights.